Pharmacologic class (EPC) · 4 drug pages

Thiazide-like diuretic: adverse event reports filed with FDA

9,368 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

9,368
reports across the class: 0.1% of all reports; 611
reports, 12 months to June 2026: 651 in the 12 months before; 90%
marked serious by the reporter: 57.4% across all reports; 4
drugs with a page: brand and generic names counted separately

Thiazide-like diuretic is a pharmacologic class (an FDA Established Pharmacologic Class) with 4 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 9,368 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026.

611 reports arrived in the 12 months to June 2026, close to the 651 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 90% of the class's reports are marked serious, 7.5% record death among the outcomes and 55.4% record hospitalisation, as reported.

Across the class the reactions recorded most often are hyponatraemia (16.8%), hypokalaemia (9.9%) and acute kidney injury (9.1%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Indapamide	generic	5,557	361	98.5%	Hyponatraemia
Chlorthalidone	generic	1,625	165	82%	Hyponatraemia
Metolazone	generic	1,352	58	88.7%	Acute kidney injury
EdarbyclorAzilsartan kamedoxomil and chlorthalidone	brand	834	27	51.3%	Dizziness

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Hyponatraemialow blood sodium16.8%1,570
Hypokalaemialow blood potassium9.9%926
Acute kidney injurysudden loss of kidney function9.1%850
Dizzinesslight-headedness or unsteadiness6.5%606
Hypotensionlow blood pressure6.2%579
Drug interactionan interaction between medicines5.7%538
Nauseafeeling sick5.3%500
Dyspnoeashortness of breath5.1%482
Drug ineffectivethe medicine did not work as expected5%469
Confusional stateconfusion5%465
Vomitingbeing sick4.4%414
Falla fall4%372
Malaisegeneral feeling of being unwell4%371
Astheniaweakness or lack of energy3.9%367
Dehydrationdehydration3.9%362
Fatiguetiredness3.6%339
Headachehead pain3.5%330
Diarrhoealoose or frequent stools3.5%327
Hypertensionhigh blood pressure3.1%289
Oedema peripheralswelling of the legs, ankles or hands3%283
Syncopefainting2.9%272
Atrial fibrillationan irregular heart rhythm2.7%257
Blood creatinine increasedraised creatinine, a kidney test2.7%249
Blood pressure increaseda raised blood pressure reading2.6%240
Condition aggravatedthe condition being treated got worse2.5%231

Solid bar: share of all class reports. Hollow bar: the median share across the 4 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death7.5%704

Life-threatening8.6%809

Hospitalisation (initial or prolonged)55.4%5,193

Disability2.7%257

Congenital anomaly0.5%45

Other serious50%4,683

Not serious10%933

Patient age

Under 20.1%8

2 to 110.1%13

12 to 170.1%14

18 to 444.7%443

45 to 6422.7%2,128

65 to 7422.1%2,068

75 and over27.1%2,536

Age not given23%2,158

Who reported

Physician28.9%2,704

Pharmacist18.2%1,705

Other health professional28.5%2,673

Lawyer0%0

Consumer or non-health professional20.8%1,951

Not given3.6%335

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Thiazide-like diuretic reports

Which drugs are in the Thiazide-like diuretic class on this site?

Indapamide, Chlorthalidone, Metolazone and Edarbyclor. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

9,368 reports through June 2026, 611 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

hyponatraemia (16.8%), hypokalaemia (9.9%), acute kidney injury (9.1%), dizziness (6.5%) and hypotension (6.2%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.